GH Axis Research
Studied for its interaction with growth hormone secretion pathways.
Overview
CJC/IPA combines CJC-1295 No DAC, a growth-hormone-releasing hormone (GHRH) analog, with Ipamorelin, a selective growth hormone secretagogue, studied together for their complementary roles in GH-axis research.
Suria's CJC/IPA is formulated to high purity and independently verified prior to release, supporting consistent, well-documented combination-protocol research.
Research Use Only. Not for human or veterinary use.
Specifications
Third-Party Testing
Available third-party analytical documentation for CJC/IPA can be reviewed for applicable batches through Suria's Batch Documentation system. We believe documentation should be held to the same standard as the research it supports.
Certificates of Analysis will be available at time of launch.
Research Highlights
Studied for its interaction with growth hormone secretion pathways.
A frequent focus of lean-mass and body-composition research models.
Studied for a targeted mechanism of action within the GH secretagogue class.
Consistent, well-documented starting material for endocrine pathway research.
Storage
Store at −20°C, protected from light and moisture, until ready for reconstitution.
Store at 2–8°C and use within the recommended window for your protocol.
Avoid repeated freeze-thaw cycles to help preserve peptide integrity across a research protocol.
Research Use Only. Not for human consumption.
Frequently Asked Questions
Batch Documentation